Aethlon Medical Announces Bird Flu Research Collaborations.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today it will initiate research studies to test the in vitro effectiveness of the Aethlon Hemopurifier[R] to capture H5N1 Avian Influenza. Testing of the Hemopurifier[R] will be conducted through collaborations with researchers at Commonwealth Biotechnologies and Battelle Biomedical Research Center. Both organizations are approved by the Department of Health and Human Services (HHS) under the Select Agent Programs of the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) to carry out studies on highly pathogenic avian influenza. At present, H5N1 Avian Influenza does not pass efficiently in human-to-human transmissions. However, it is feared the virus, whose mortality rate in infected humans exceeds 60%, will evolve to spark global pandemic. Scientific publications attribute high mortality rates to evidence of H5N1 spreading through the bloodstream to organs and other regions of the body not normally affected by influenza viruses.

"We are grateful to colleagues at Commonwealth and Battelle for allowing us the opportunity to demonstrate the ability of our Hemopurifier[R] to capture highly pathogenic forms of influenza, including H5N1," stated Aethlon Chairman and CEO, James A. Joyce. "By targeting the systemic infection occuring in the blood of H5N1 patients, the Hemopurifier[R] would be positioned to fill an significant void not addressed by other therapeutics," concluded Joyce.

About Battelle

Battelle provides solutions to some of the world's most important challenges through its three global businesses: National Security, Energy Science and Technology, and Health and Life Sciences. Battelle is the world's largest independent research and development organization with technology contributions that find their way into hundreds of commercial products each year. Conducting $3.8 billion in global R&D annually, Battelle oversees 20,000 employees in more than 120 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy. Headquartered in Columbus, Ohio, and established in 1929 as a non-profit charitable trust. For more information, visit www.battelle.org.

About Commonwealth Biotechnologies (CBI)

The CBI group of companies offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Tripos Discovery Research, Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 120 staff in world-class laboratories. For more information, visit CBI on the web at www.cbi-biotech.com.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device to treat infectious disease. The Hemopurifier[R] addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier([R])are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier[R] in a 24-treatment human study and has received approval to continue further humans studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier([R])as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information on Aethlon Medical and its Hemopurifier([R]) technology can be accessed at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.